Sign in or Register   Sign in or Register
  |  

Mouse Anti-CD274 Recombinant Antibody (CBXC-2727) (CBMAB-C5823-CQ)

This product is a mouse antibody that recognizes CD274. The antibody CBXC-2727 can be used for immunoassay techniques such as: WB, IF.
See all CD274 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBXC-2727
Antibody Isotype
IgG1
Application
WB, IF

Basic Information

Immunogen
Full length human recombinant protein of human CD274(NP_054862)
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.3, 1% BSA, 50% glycerol
Preservative
0.02% sodium azide
Concentration
1 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
CD274 Molecule
Introduction
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Entrez Gene ID
29126
UniProt ID
Q9NZQ7
Alternative Names
CD274 Molecule; CD274 Antigen; B7 Homolog 1; Programmed Cell Death 1 Ligand 1; PDCD1 Ligand 1; PDCD1LG1; PDCD1L1;

Verocq, C., Decaestecker, C., Rocq, L., De Clercq, S., Verrellen, A., Mekinda, Z., ... & D'haene, N. (2020). The daily practice reality of PD‑L1 (CD274) evaluation in non‑small cell lung cancer: A retrospective study. Oncology letters, 19(5), 3400-3410.

Riemann, D., Schütte, W., Turzer, S., Seliger, B., & Möller, M. (2020). High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Cancers, 12(10), 2966.

Kim, J. Y., Lee, K. H., Kang, J., Borcoman, E., Saada-Bouzid, E., Kronbichler, A., ... & Gamerith, G. (2019). Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers, 11(11), 1699.

Fabrizio, F. P., Trombetta, D., Rossi, A., Sparaneo, A., Castellana, S., & Muscarella, L. A. (2018). Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic advances in medical oncology, 10, 1758835918815598.

Huang, C. Y., Chiang, S. F., Ke, T. W., Chen, T. W., You, Y. S., Chen, W. T. L., & Chao, K. C. (2018). Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer. Scientific reports, 8(1), 1-10.

Clavé, S., Pijuan, L., Casadevall, D., Taus, Á., Gimeno, J., Hernández‐Llodrà, S., ... & Salido, M. (2018). CD 274 (PDL 1) and JAK 2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients. Histopathology, 72(2), 259-269.

Yang, L., Cai, Y., Zhang, D., Sun, J., Xu, C., Zhao, W., ... & Pan, C. (2018). miR-195/miR-497 regulate CD274 expression of immune regulatory ligands in triple-negative breast cancer. Journal of breast cancer, 21(4), 371-381.

Sun, J., Lian, M., Ma, H., Wang, R., Ma, Z., Wang, H., ... & Fang, J. (2018). Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma. Molecular medicine reports, 17(3), 3859-3869.

Lee, S. J., Jun, S. Y., Lee, I. H., Kang, B. W., Park, S. Y., Kim, H. J., ... & Kim, J. G. (2018). CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. Journal of cancer research and clinical oncology, 144(6), 1005-1014.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CD274 Recombinant Antibody (CBXC-2727)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare